Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Global Pharma Market Grows 8.3% in 2022, Humira Top-Seller Drug: IQVIA
June 21, 2023
- ASKA Seeks Pediatric Indication for Rifxima in Japan
June 21, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Daiichi Sankyo Chair Snares 402 Million Yen in FY2022: Securities Report
June 20, 2023
- Entyvio SC Now Available in Japan: Takeda
June 20, 2023
- Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
June 19, 2023
- Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
June 19, 2023
- As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
- PharmaEssentia Eyes Japan Sales of 50 Billion Yen in 2030
June 16, 2023
- Astellas Inks Protein Degrader Deal with Cullgen
June 16, 2023
- Opdivo Filed for Malignant Epithelial Tumors in Japan
June 16, 2023
- Azilva, Allermist Authorized Generics to Hit Japan Market on June 16
June 16, 2023
- Japan Regenerative Drug Market to Reach 72.3 Billion Yen in 2030: Fuji Keizai
June 16, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
- AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
- AbbVie Goes Solo in Humira Marketing and Promotion in Japan
June 14, 2023
- Argenx Makes World’s 1st Filing in Japan for Vyvgart’s ITP Use
June 14, 2023
- Keytruda Filed for Biliary Tract Cancer in Japan
June 14, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…